January 2022 in “Gastro Hep advances” This case report describes a woman diagnosed with Cronkhite-Canada syndrome whose gastrointestinal symptoms and alopecia improved significantly after systemic prednisone treatment, with no recurrence four years after a second treatment course.
62 citations
,
March 2011 in “European journal of endocrinology” This study found that parents identified with cryptic NCCAH through genetic testing are mostly asymptomatic but may experience temporary female infertility and require glucocorticoid stress coverage in specific circumstances.
14 citations
,
August 2009 in “Cancer epidemiology” This study found that AHCC significantly reduced alopecia caused by Ara-C in neonatal rats and improved liver function affected by 6-MP and MTX in mice.
April 2018 in “Journal of Investigative Dermatology” This study observed that β-catenin overexpression in human squamous cell carcinoma cells led to increased CREB expression, which significantly enhanced clonogenic activity, suggesting CREB as a β-catenin-regulated factor promoting cancer characteristics.
24 citations
,
June 2012 in “BMC Research Notes” This study outlines the Human Gene Correlation Analysis tool, which classifies human genes by coexpression levels and identifies overrepresented annotation terms in correlated gene groups, with no new clinical results reported.
1 citations
,
January 2024 in “International Journal of Epidemiology” This study describes the ongoing HABIT study in Taicang, China, which aims to identify risk factors and the relationship between cardiovascular and neurodegenerative diseases among 10,357 adults, by collecting and analyzing long-term data on health, lifestyle, and biological specimens. Results are not yet available.
July 2024 in “JAAD Case Reports” This study reports two cases of central serous chorioretinopathy developing after intralesional corticosteroid injections to the scalp for alopecia areata, suggesting a potential association that warrants cautious use and monitoring for ocular complications.
May 2023 in “Frontiers in Endocrinology” This study found that tildacerfont treatment in males with congenital adrenal hyperplasia reduced androgen levels and improved markers of testicular function, suggesting potential benefits for male reproductive health.
2 citations
,
May 2021 in “Clinical Pharmacology in Drug Development” This phase 1 study reported that after administering supratherapeutic doses of cortexolone 17α‐propionate, a topical antiandrogen intended for hair loss treatment, there was no effect on the QTc interval, indicating no measurable cardiac safety concerns in the concentration range tested.
6 citations
,
December 2015 in “Medicine” This review discusses Cronkhite-Canada syndrome, highlighting a relatively mild case and suggesting that it may be a more benign and possibly reversible condition with treatment, but reports no new clinical results.
September 2025 in “Genes” In this study, researchers reported that specific gene polymorphisms in Jiangnan cashmere goats, particularly SNPs in the HOXC13 and WNT4 genes, were significantly associated with key economic traits like birth weight and yearling weight, providing molecular markers for breeding and enhancing economic trait stability.
2 citations
,
August 2022 in “World Journal of Clinical Cases” In this study, researchers found multiple somatic mutations and copy number variations in a patient with Cronkhite-Canada syndrome, providing novel insights into its potential genetic mechanisms.
9 citations
,
February 2023 in “Medicine” This review discusses the potential of traditional Chinese medicine to relieve clinical symptoms in cases of CCS and emphasizes the need for further large-scale, long-term studies to verify these effects.
June 2024 in “Journal of Clinical Oncology” In this retrospective study, combining TACE with Donafenib showed promising results as a first-line treatment for Chinese patients with unresectable hepatocellular carcinoma, yielding a median progression-free survival of 12.8 months and a one-year overall survival rate of 87.5%, along with a favorable safety profile.
October 2024 in “Journal of the Endocrine Society” This study found that certain CYP21A2 mutations significantly reduce enzyme activity, contributing to non-classic congenital adrenal hyperplasia phenotypes, which may aid in enhancing diagnosis and treatment strategies.
1 citations
,
May 2017 in “Journal of Clinical Oncology” This study found that applying BPM 31543 twice daily was safe, well-tolerated, and showed signs of reducing chemotherapy-induced alopecia in women receiving taxane-based chemotherapy.
July 2023 in “JAAD Case Reports”
August 2023 in “Gastroenterology” This study describes the diagnosis and successful management of Cronkhite-Canada syndrome in a 78-year-old man, highlighting improvement in symptoms and endoscopic findings after treatment with prednisone and supportive therapies.
7 citations
,
September 2017 in “Pharmacoepidemiology and Drug Safety” This study observed a strong overall reduction in the use of CPA/EE in the Netherlands, despite similar proportions of users with acne or other hyperandrogenic conditions before and after the referral procedure.
July 2018 in “Hair transplant forum international” This abstract contains only author affiliations and mentions the Asian Association of Hair Restoration Surgeons, without presenting any new research findings.
October 2024 in “Journal of the Endocrine Society” This study examined uncharacterized CYP21A2 gene variants related to non-classic congenital adrenal hyperplasia and found that several mutations reduce enzyme activity, which may help improve diagnostic and treatment strategies.
40 citations
,
March 2003 in “The journal of small animal practice/Journal of small animal practice” In this case study, medical management with trilostane improved clinical signs and normalized serum chemistry in a dog diagnosed with adrenal-dependent hyperadrenocorticism over 80 weeks of treatment.
March 2022 in “JAAD case reports” This case report highlights the importance of maintaining clinical suspicion for tinea incognito in patients with central centrifugal cicatricial alopecia who do not respond to typical corticosteroid treatments, as misdiagnosis can complicate treatment.
January 2014 in “Duo Research Archive (University of Oslo)” This study found that steroid hormone treatments significantly reduced mRNA expression of certain Ca2+-activated K+ channel genes in Atlantic cod pituitary cells, suggesting a potential role in sexual maturation regulation.
January 2026 in “JCEM Case Reports” This case report presents a rare instance of recurrent ACTH-independent Cushing’s syndrome due to PBMAH, coinciding with the development of a pheochromocytoma, highlighting the need for thorough reevaluation in similar recurring cases.
January 2024 in “Bratislavské lekárske listy/Bratislava medical journal” This study examined the vasorelaxant effects of two similar alkaloids, chloroquine and cinchonine, in a model of smooth muscle contractions induced by phenylephrine. Results are not reported in the abstract.
6 citations
,
September 2002 in “Acta pædiatrica” This case study observed that long-term itraconazole and budesonide use in a cystic fibrosis patient led to iatrogenic Cushing's syndrome due to inhibited metabolic clearance of budesonide, suggesting a need for regular adrenal insufficiency monitoring in such treatments.
January 2025 in “JCEM Case Reports” In this case report, a 21-year-old woman diagnosed with ACTH-independent Cushing syndrome showed improvement in symptoms, including a more regular menstrual cycle and lower hirsutism, after starting treatment with ketoconazole, although she developed hypertension.
7 citations
,
August 2025 in “European Journal of Endocrinology” The authors concluded that incorporating routine endocrinology consultations into transplant care could address CNI-related endocrine toxicities, but prospective studies are needed to assess the impact on graft and patient survival.
June 2024 in “ESMO Gastrointestinal Oncology” The BAYONET trial is a phase II study designed to assess the efficacy and safety of combining encorafenib, binimetinib, and cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer that is resistant to encorafenib plus cetuximab; results are not yet reported.